Author(s): Barry EM, Pasetti MF, Sztein MB, Fasano A, Kotloff KL,
Abstract Share this page
Abstract Renewed awareness of the substantial morbidity and mortality that Shigella infection causes among young children in developing countries, combined with technological innovations in vaccinology, has led to the development of novel vaccine strategies in the past 5 years. Along with advancement of classic vaccines in clinical trials and new sophisticated measurements of immunological responses, much new data has been produced, lending promise to the potential for production of safe and effective Shigella vaccines. Herein, we review the latest progress in Shigella vaccine development within the framework of persistent obstacles.
This article was published in Nat Rev Gastroenterol Hepatol
and referenced in Journal of Vaccines & Vaccination